JP2007534699A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007534699A5 JP2007534699A5 JP2007509736A JP2007509736A JP2007534699A5 JP 2007534699 A5 JP2007534699 A5 JP 2007534699A5 JP 2007509736 A JP2007509736 A JP 2007509736A JP 2007509736 A JP2007509736 A JP 2007509736A JP 2007534699 A5 JP2007534699 A5 JP 2007534699A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- hmg
- coa reductase
- composition according
- statin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 24
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 6
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 4
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims 4
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 4
- 241000238876 Acari Species 0.000 claims 3
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 claims 3
- 239000002876 beta blocker Substances 0.000 claims 3
- 229940097320 beta blocking agent Drugs 0.000 claims 3
- 125000002091 cationic group Chemical group 0.000 claims 3
- 150000002148 esters Chemical group 0.000 claims 3
- 150000002596 lactones Chemical class 0.000 claims 3
- 150000003180 prostaglandins Chemical class 0.000 claims 3
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 2
- VDSBXXDKCUBMQC-HNGSOEQISA-N (4r,6s)-6-[(e)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@H]2OC(=O)C[C@H](O)C2)=C1 VDSBXXDKCUBMQC-HNGSOEQISA-N 0.000 claims 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 2
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 claims 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 2
- 229960005370 atorvastatin Drugs 0.000 claims 2
- 229950003040 dalvastatin Drugs 0.000 claims 2
- 229960003765 fluvastatin Drugs 0.000 claims 2
- 229960004844 lovastatin Drugs 0.000 claims 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 2
- 229950009116 mevastatin Drugs 0.000 claims 2
- 229960002797 pitavastatin Drugs 0.000 claims 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 2
- 229960002965 pravastatin Drugs 0.000 claims 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 229960000672 rosuvastatin Drugs 0.000 claims 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 2
- 229960002855 simvastatin Drugs 0.000 claims 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 230000004406 elevated intraocular pressure Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 230000004493 normal intraocular pressure Effects 0.000 claims 1
- 210000001585 trabecular meshwork Anatomy 0.000 claims 1
- 0 C*CCC[C@](C)C(O)O[C@@]1C(*C(C)C=C2)C2=CCC1 Chemical compound C*CCC[C@](C)C(O)O[C@@]1C(*C(C)C=C2)C2=CCC1 0.000 description 5
- HZZWGNMIEMOPPI-UHFFFAOYSA-N CC(C)C(C1C)=NC(CCS(C)(=O)=O)=NC1(C)c(cc1)ccc1F Chemical compound CC(C)C(C1C)=NC(CCS(C)(=O)=O)=NC1(C)c(cc1)ccc1F HZZWGNMIEMOPPI-UHFFFAOYSA-N 0.000 description 1
- PNDSBJLNZUIHGR-UHFFFAOYSA-N CC[n](c(C(C)C)c1C(Nc2ccccc2)O)c(-c(cc2)ccc2F)c1-c1ccccc1 Chemical compound CC[n](c(C(C)C)c1C(Nc2ccccc2)O)c(-c(cc2)ccc2F)c1-c1ccccc1 PNDSBJLNZUIHGR-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56546904P | 2004-04-26 | 2004-04-26 | |
| PCT/US2005/014255 WO2005105069A1 (en) | 2004-04-26 | 2005-04-25 | Statins for the treatment of ocular hypertension and glaucoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007534699A JP2007534699A (ja) | 2007-11-29 |
| JP2007534699A5 true JP2007534699A5 (enExample) | 2008-01-17 |
Family
ID=34966865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007509736A Pending JP2007534699A (ja) | 2004-04-26 | 2005-04-25 | 高眼圧症及び緑内障の治療ためのスタチン |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20050239871A1 (enExample) |
| EP (1) | EP1740164B1 (enExample) |
| JP (1) | JP2007534699A (enExample) |
| KR (2) | KR20110091600A (enExample) |
| CN (1) | CN1946384B (enExample) |
| AT (1) | ATE404189T1 (enExample) |
| AU (1) | AU2005237543B2 (enExample) |
| BR (1) | BRPI0510245A (enExample) |
| CA (1) | CA2560167A1 (enExample) |
| CY (1) | CY1108490T1 (enExample) |
| DE (1) | DE602005008935D1 (enExample) |
| DK (1) | DK1740164T3 (enExample) |
| ES (1) | ES2311986T3 (enExample) |
| MX (1) | MXPA06012225A (enExample) |
| PL (1) | PL1740164T3 (enExample) |
| PT (1) | PT1740164E (enExample) |
| SI (1) | SI1740164T1 (enExample) |
| WO (1) | WO2005105069A1 (enExample) |
| ZA (1) | ZA200607988B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005053683A1 (en) * | 2003-11-26 | 2005-06-16 | Duke University | A method of preventing or treating glaucoma |
| WO2007070866A2 (en) * | 2005-12-16 | 2007-06-21 | Alcon, Inc. | Control of intraocular pressure using alk5 modulation agents |
| PL2018153T3 (pl) | 2006-04-26 | 2012-09-28 | Rosemont Pharmaceuticals Ltd | Ciekłe kompozycje doustne |
| US20090202524A1 (en) * | 2007-10-31 | 2009-08-13 | Alcon Research, Ltd. | Pai-1 expression and activity inhibitors for the treatment of ocular disorders |
| ES2330184B1 (es) * | 2008-06-03 | 2010-07-05 | Neuron Biopharma, S.A. | Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores. |
| US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| CN102093984B (zh) * | 2010-11-23 | 2012-07-04 | 清华大学 | 一种杂合酶P450sca2-BMR及其编码基因与应用 |
| CN104902892A (zh) | 2012-02-02 | 2015-09-09 | 悉尼大学 | 泪液膜稳定性的改进 |
| GB201611782D0 (en) * | 2016-07-06 | 2016-08-17 | Optibiotix Ltd | Composition |
| US10696638B2 (en) | 2017-12-26 | 2020-06-30 | Industrial Technology Research Institute | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same |
| WO2025147589A1 (en) * | 2024-01-05 | 2025-07-10 | Osanni Bio, Inc. | Implants, compositions, and methods for treating retinal diseases and disorders |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2534580A1 (fr) * | 1982-10-13 | 1984-04-20 | Synthelabo | Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent |
| FR2585708B1 (fr) * | 1985-07-31 | 1989-07-07 | Sanofi Sa | Derives aminoalcools peptidiques inhibiteurs de la resine et des proteases acides, leur procede de preparation et leur application en therapeutique |
| US5151444B1 (en) * | 1987-09-18 | 1999-07-06 | R Tech Ueno Ltd | Ocular hypotensive agents |
| US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| ES2213504T1 (es) * | 1988-09-06 | 2004-09-01 | Pfizer Health Ab | Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular. |
| FR2647675B1 (fr) * | 1989-06-05 | 1994-05-20 | Sanofi | Utilisation d'un derive de la statine dans le traitement des affections oculaires |
| JPH04243835A (ja) * | 1990-08-29 | 1992-08-31 | Pfizer Inc | 高眼圧症又は緑内障治療用薬剤組成物及び治療方法 |
| US5352708A (en) * | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5510383A (en) * | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
| US5599535A (en) * | 1995-06-07 | 1997-02-04 | Regents Of The University Of California | Methods for the cyto-protection of the trabecular meshwork |
| US6586425B2 (en) * | 1996-02-21 | 2003-07-01 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
| US6569461B1 (en) * | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
| EP1322306A2 (en) * | 2000-09-19 | 2003-07-02 | NovImmune S.A. | Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent |
| US20030065020A1 (en) * | 2001-07-13 | 2003-04-03 | Catharine Gale | Treatment of macular degeneration |
| US20030195167A1 (en) * | 2002-04-15 | 2003-10-16 | Kowa Co., Ltd. | PTX3-gene expression inhibitor |
| JP2004149480A (ja) * | 2002-10-31 | 2004-05-27 | Saisentan Igaku Kenkyusho:Kk | 経口又は経皮投与用の眼科疾患治療剤 |
| US20040248972A1 (en) * | 2003-05-16 | 2004-12-09 | Ambit Biosciences Corporation | Compounds and uses thereof |
| CA2523808A1 (en) * | 2003-05-16 | 2004-12-23 | Ambit Biosciences Corporation | Pyrrole compounds and uses thereof |
| US20060241122A1 (en) * | 2003-05-30 | 2006-10-26 | Lee Margaret S | Combination therapy for the treatment of neoplasms |
| WO2005053683A1 (en) * | 2003-11-26 | 2005-06-16 | Duke University | A method of preventing or treating glaucoma |
| US20090202524A1 (en) * | 2007-10-31 | 2009-08-13 | Alcon Research, Ltd. | Pai-1 expression and activity inhibitors for the treatment of ocular disorders |
-
2005
- 2005-04-25 AU AU2005237543A patent/AU2005237543B2/en not_active Ceased
- 2005-04-25 SI SI200530460T patent/SI1740164T1/sl unknown
- 2005-04-25 ES ES05738648T patent/ES2311986T3/es not_active Expired - Lifetime
- 2005-04-25 CN CN2005800130061A patent/CN1946384B/zh not_active Expired - Fee Related
- 2005-04-25 WO PCT/US2005/014255 patent/WO2005105069A1/en not_active Ceased
- 2005-04-25 BR BRPI0510245-6A patent/BRPI0510245A/pt not_active IP Right Cessation
- 2005-04-25 KR KR1020117018000A patent/KR20110091600A/ko not_active Withdrawn
- 2005-04-25 MX MXPA06012225A patent/MXPA06012225A/es active IP Right Grant
- 2005-04-25 ZA ZA200607988A patent/ZA200607988B/xx unknown
- 2005-04-25 JP JP2007509736A patent/JP2007534699A/ja active Pending
- 2005-04-25 DK DK05738648T patent/DK1740164T3/da active
- 2005-04-25 PT PT05738648T patent/PT1740164E/pt unknown
- 2005-04-25 AT AT05738648T patent/ATE404189T1/de active
- 2005-04-25 PL PL05738648T patent/PL1740164T3/pl unknown
- 2005-04-25 EP EP05738648A patent/EP1740164B1/en not_active Expired - Lifetime
- 2005-04-25 US US11/114,512 patent/US20050239871A1/en not_active Abandoned
- 2005-04-25 DE DE602005008935T patent/DE602005008935D1/de not_active Expired - Lifetime
- 2005-04-25 CA CA002560167A patent/CA2560167A1/en not_active Abandoned
-
2006
- 2006-11-15 KR KR1020067023958A patent/KR101071192B1/ko not_active Expired - Fee Related
-
2008
- 2008-11-07 CY CY20081101271T patent/CY1108490T1/el unknown
-
2010
- 2010-11-08 US US12/941,639 patent/US20110098314A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007534699A5 (enExample) | ||
| US20110098314A1 (en) | Statins for the treatment of ocular hypertension and glaucoma | |
| JP2010077141A5 (enExample) | ||
| CA2645884A1 (en) | Substituted chromanol derivatives and their use | |
| AR041089A1 (es) | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas | |
| WO2008062476A2 (en) | Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof | |
| WO2013066279A1 (en) | Solid dosage forms comprising ezetimibe | |
| WO2006100036A1 (en) | 3, 4-substituted pyrrolidine derivatives for the treatment of hypertension | |
| US6083985A (en) | Medicinal composition | |
| CA2710791A1 (en) | Pyripyropene derivatives having an acat2-inhibiting activity | |
| JP2007512347A5 (enExample) | ||
| WO2011139256A2 (en) | Stable rosuvastatin formulations | |
| JP2011518828A5 (enExample) | ||
| JP2008208038A5 (enExample) | ||
| JPWO2012046772A1 (ja) | リンパ浮腫予防治療剤 | |
| CA2443235A1 (en) | Pharmaceutical compositions comprising ascomycin | |
| EA200800071A1 (ru) | Производные бензофуранила как ингибиторы 5-нт6-рецептора | |
| JP2005522490A5 (enExample) | ||
| JP2021533190A (ja) | ＬＤＬコレステロールの細胞内クリアランスを増強しかつスタチンとの併用療法で効力を高めかつ副作用を減らすための、カルバメートβフェニルエタノールアミン類似体の新規使用法 | |
| RU2007149337A (ru) | Новый способ лечения гиперлипидемии | |
| AU2001282541B2 (en) | Medicinal compositions | |
| DK1728508T3 (da) | Farmaceutisk produkt til forebyggelse eller behandling af hyppig vandladning eller inkontinens | |
| CA2798707A1 (en) | Association of xanthine oxidase inhibitors and statins and use thereof | |
| JP5336847B2 (ja) | スタチンによる慢性閉塞性肺疾患治療 | |
| JP2006176498A5 (enExample) |